MITOKSANTRON (Mitoxantrone). (name drug company AWD, Germany). 1, 4-Digidroksi-5, 8-bis [2-[(2-hydroxyethyl) amino) - ethyl] - amine o] anthraquinone.

     Synonyms : Mitozantrone, Novatron.

     Available as hydrochloride. Is synthetic anticancer tool. On chemical structure (a antrahinonovogo nucleus) has similarities with antibiotic therapy antratsiklinovymi (see Doksorubitsin, Rubomitsin).

     Applied Novantrone with breast cancer to the presence of metastases, lymphoma (but not with chlamydia), acute leukaemia in adults (including blastnom Stroke), and worsening of chronic mieloleykoza with hepatic cell cancer.

     Enter solution mitoksantrona strictly intravenous slowly (no faster than 5 min), or in a short drip Infusion (in the 15 - 30 min). Dissolve product (respectively content in vial), in 50 or 100 ml isotonic solution of sodium chloride or glucose.

     With breast cancer, non-Hodgkin's lymphoma and hepatic cancer cell, enter 14 mg per m2 of body surface 1. Repeated introduction produce usually 21 days. In general condition and the patient's blood oppression, first imposed at the rate of 12 mg / m 2, and repeated at intervals of 3 to 4 weeks.

     In a repeat dose picked with an eye on the haematopoietic system. The number of cells in the blood after the drug must be at least 1, 5 x 10 9 / L, platelets and 50 x 10 9 / L.

     Usually, after mitoksantrona, the number of leukocyte and thrombocyte restored within 21 days or sooner. In these cases, repeat the introduction initial dose 21 days. If after 21 days there is no effect to wait to reconstruct the blood.

     If the number of cells in the blood after the drug decreases to 1, 5 x 10 9 / L or more, and platelets 50 x 10 9 / L or more, then regardless of the period of reconstruction following picture blood dose reduced by 2 mg / m2, with the number of leukocyte less than 1 ? 10 9 / L and platelets less than 25 x 10 9 / L follow reduce the dose of 4 mg / m 2. In both cases, subsequent injections to the restoration of paintings blood.

     In acute leukemia impose Novantrone to 10 - 12 mg / m 2 / day for 5 days. The course of treatment can be repeated after the events of oppression kostnomozgovogo blood.

     In the case of combined therapy with other drugs Novantrone appointed in doses of 2 to 4 mg / m 2 less than monotherapies.

     In all ways of accumulated dose of treatment should not exceed 200 mg / m 2.

     In applying mitoksantrona possible side effects. Like other similar chemotherapy drugs, it is the oppression of blood (radiation, thrombocytopenia, less-eritrotsitopeniya). Like doxorubicin and other antratsiklinovym antibiotics Novantrone has kardiotoksicheskoe effect. There may be nausea, vomiting, diarrhea, general weakness, increased body temperature, amenorrhea, Alopecia and other side effects.

     The drug is not suitable for individual sensitivity, pregnancy, breast-feeding. With caution should be used in the preparation pantsitopenii, severe infection, severe liver and kidney failure, in patients with severe heart diseases (including in history).

     With regard to the content in vials with mitoksantronom sodium disulfita possible in some cases neperenosimost drug patients with bronchial asthma.

     Do not allow the imposition of solutions mitoksantrona under the skin (possible necrosis), and the use of drugs in the form divorced.

     Since the introduction mitoksantrona within 1 to 2 days, urine painted aqua-green, possibly also in the blue staining skin (especially in places injection), as well as Sclair.

     Method of issuance : in bottles with a capacity of 5 ml containing 10 mg mitoksantrona (Novantrone AWD 10), corresponding to 11, 64 mg mitoksantrona hydrochloride, with the addition of 0.5 mg sodium disulfita and in bottles with a capacity of 12, 5 ml containing 25 mg mitoksantrona (Novantrone A WD 25), which corresponds to 29, 1 mg mitoksantrona hydrochloride; with the addition of 1, 25 mg sodium disulfita.

     Storage : List A. In the dark spot.

Materials allowed to copy only with the active hyperlink to the handbook of medicines